Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a breast cancer drug improve abortion care?

NCT ID NCT07767435

Disease control Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study tests whether adding letrozole, a drug commonly used for breast cancer, to the standard medication misoprostol can improve the complete termination of second-trimester pregnancies (14-20 weeks). The trial will compare the combination against misoprostol alone in 80 women with a failed pregnancy. The main goal is to see if the combination leads to a higher rate of complete abortion, potentially making the process safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
letrozole combined with misoprostol
What this could lead to
If adding letrozole works, it could make second-trimester abortion procedures faster and more complete, reducing the need for additional surgical intervention.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not be conclusive. Adding letrozole could also increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women aged 18-45 years. * Failed pregnancy. * Gestational age between 14 and 20weeks, confirmed by ultrasonography on the day of admission. * Hemoglobin concentration \>9 g/dL. * Closed cervix. * Absence of products of conception in the cervical canal. \- Exclusion Criteria: * Previous attempt to terminate the current pregnancy. * Molar pregnancy (hydatidiform mole). * Pathological uterine lesions including uterine fibroids and congenital uterine malformations. * Cardiac disease. * Renal disease. * Hemorrhagic disorders. * Body mass index (BMI) \>35 kg/m². * Documented hypersensitivity or allergy to letrozole, misoprostol, or any of the study medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abortion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pregnancy loss, recurrent, susceptibility to, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abortion Abortion induced complicated

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.